首页 正文

Outcomes in Bimekizumab Treated Psoriasis Patients With Prior IL-17 Inhibitor Failure

{{output}}
Despite advancements in psoriasis therapeutics, biologic discontinuation and switching still happen frequently, with the most common reasons being lack of efficacy or treatment intolerance. Conventional teaching has been to switch out of the class (inter-class... ...